Status:
UNKNOWN
SVF Combined With Functional Self-assembling Peptide Nanofiber Hydrogels in the Treatment of Spinal Cord Injury
Lead Sponsor:
Kunming Tongren Hospital
Conditions:
Safety Issues
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Traumatic spinal cord injury (SCI) is a severe medical problem experienced by people worldwide with high mortality and long term morbidity. Although progress has been made in understanding cellular an...
Eligibility Criteria
Inclusion
- Male or female adults, 18-60 years of age, with a clinical diagnosis of chronic traumatic SCI (≥ 3 months after SCI)
- Neurological examination: ASIA-A
- Both the spinal and neurological levels of injury were between T1-T12
- Subjects must be able to read, write and complete visual analogue scale
- Voluntarily signs and dates an informed Consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific procedures.
Exclusion
- Subjects with osteoporosis or had joint disease
- Severe head injury
- Severe pressure sore
- Sign of kidney, cardiovascular, liver disorders
- Subjects with internal medical and/or infectious diseases (including but not limited to Hepatitis B and HIV carriers)
- Pregnant women or women at lactation stages
- Medically or mentally unstable according to the judgment of the investigator
- History of multiple sclerosis or peripheral demyelination
- Any criteria which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol
Key Trial Info
Start Date :
July 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 15 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05967325
Start Date
July 15 2023
End Date
July 15 2025
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kunming Tongren Hospital
Kunming, Yunnan, China, 650000